Navigation Links
For Erectile Dysfunction, Physicians Indicate That Opportunity Exists for Emerging Therapies with Improved Efficacy in Difficult-to-Treat Patient Subpopulations
Date:4/15/2009

A Drug With Greater Efficacy than Levitra for Patients with Hypertension Priced at a Five Percent Discount to Levitra Would Earn a 50 Percent Patient Share in the U.S., According to a New Report from Decision Resources

WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although surveyed primary care physicians (PCPs) are generally satisfied with the efficacy of available phosphodiesterase type 5 (PDE5) inhibitors such as Pfizer's Viagra, Eli Lilly's Cialis and Bayer Healthcare/Schering-Plough/GlaxoSmithKline's Levitra, they are less satisfied with the efficacy of this drug class in difficult-to-treat patient subpopulations. PCPs' satisfaction with available PDE5 inhibitors on key measures of clinical efficacy suggests that opportunity exists for improvement in the treatment of erectile dysfunction patients with comorbid conditions such as hypertension and diabetes.

The new report entitled Erectile Dysfunction: Physicians Seek Improvements in Efficacy for Underserved Patients and Product Differentiation on Onset and Duration of Action finds that a therapy that provides greater improvement in erectile function than Levitra in patients with hypertension and that is priced at a five percent discount to Levitra would earn a 50 percent patient share in the United States and a 40 percent patient share in Europe, according to surveyed U.S. primary care physicians and European general practitioners.

Additionally, while there are several second-generation PDE5 inhibitors in clinical trials for the treatment of erectile dysfunction, interviewed experts do not expect these agents to provide efficacy superior to that of currently marketed drugs in this class. The report also finds that limited reimbursement for erectile dysfunction drugs and the availability of less-expensive generic versions of Viagra beginning in 2012, will constrain the uptake of emerging PDE5 inhibitors.

"Most therapies for erectile dysfunction do not qualify for reimbursement by third-party payers," said Decision Resources Analyst Kathryn Benton, B.S. "As a result, many patients pay out-of-pocket for treatment -- this will be among the factors that will cause premium-priced emerging therapies to struggle to capture market share."

About the Report

Erectile Dysfunction: Physicians Seek Improvements in Efficacy for Underserved Patients and Product Differentiation on Onset and Duration of Action is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Decision Resources          Decision Resources, Inc.
    Christopher Comfort         Elizabeth Marshall
    781-296-2597                781-296-2563
    ccomfort@dresources.com     emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Motorcycle Seats NOT The Cause of Impotence or Erectile Dysfunction for Bikers
2. Rapid Generic Erosion of Branded Agents, Including Market-Leading Viagra, Will Cause Sales of Erectile Dysfunction Drugs to Remain Flat Over the Next Decade
3. Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment
4. Despite Sagging Economy, Viamedic Reports Solid Online Sales for Erectile Dysfunction Drugs
5. Hispanic Men Face Elevated Risk of Erectile Dysfunction
6. Researchers Examine Safety of Internet Prescriber Service Providing Erectile Dysfunction Medications
7. Researchers examine safety of Internet prescriber service providing erectile dysfunction medications
8. No-nose bicycle saddles improve penile sensation and erectile function in bicycling police officers
9. Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study
10. Lots of Sex May Prevent Erectile Dysfunction
11. Erectile dysfunction lower in men who have intercourse more often
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 04, 2016 , ... Are You Concerned About Mold In Your Home ... Indoor Air Quality Companies in VA, MD and DC, recently completed its application for ... new mold law in the district of Columbia is a good thing stated John ...
(Date:12/2/2016)... Calif. (PRWEB) , ... December 02, 2016 , ... On ... at the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who ... neoplasms (MPNs) by going above and beyond the standard of care, demonstrating leadership within ...
(Date:12/2/2016)... Portland, Maine (PRWEB) , ... December 02, 2016 , ... ... support group for caregivers of those affected by autism spectrum disorder (ASD) and other ... and Easter Seals Maine, will give parents and other caregivers the opportunity to share ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Hills, California, will be included in the 2016 “Guide to America’s Top Plastic ... based on the amalgamation of their education, experience, and professional associations. , ...
(Date:12/2/2016)... ... 02, 2016 , ... Universal Medical Systems, Inc. (UMS) the ... company to offer robotic imaging to veterinary medicine is sponsoring the appearance of ... the American Association of Equine Practitioners 62nd Annual Convention from December 4-6, 2016 ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016  Eli Lilly and Company (NYSE: ... 2017 and provide updated financial guidance for 2016 on ... conference call on that day with the investment community ... The conference call will begin at 10 ... access a live webcast of the conference call through ...
(Date:12/2/2016)... 2, 2016 CVS Health Corporation (NYSE: ... in New York City on Thursday, December 15, 2016, beginning at 8:00 a.m. ... will provide an in-depth review of the company,s strategies ... company will also discuss 2017 earnings guidance during the ... the event will be broadcast simultaneously on the Investor ...
(Date:12/2/2016)... , Dec. 2, 2016 Lianluo Smart ... or "the Company") which develops, markets and sells ... China and international markets, ... Diagnosis and Treatment New Progress Forum, co-hosted by ... Guangdong Province , Guangdong Provincial People,s Hospital ...
Breaking Medicine Technology: